In this episode Chloe & Alexander will be starting the discussion with an overview of EU HTA regulation, looking at the harmonization debate and how this came about. We then discuss JCA evaluation methodology (e.g. comparator selection, acceptability of clinical evidence), the potential new role of individual country agencies and how the joint HTA process will link to national processes. EUnetHTA21 and how the methodology is evolving with G-BA & IQWIG increasingly involved, will this be a major influence in the development of final methodology? Finally, we look at how Pharma companies should be best preparing for the implementation of the regulation.
Host: Chloe Sheppard
Guest Speaker: Alexander Natz
Produced by: Operations team
Helpful links:
#EUHTAPriorities – EUCOPE’s Five Priorities for a Successful EU HTA Procedure
Sounds of Science Podcast – Episode 1: A Future-Proof HTA system in Europe?
https://partners4access.com/whitepapers/pan-european-joint-hta-what-does-the-future-hold-for-innovative-therapies/
About Alex:
Alexander Natz is the Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) in Brussels and advises innovative pharmaceutical and biotech companies, including start-ups, in regulatory and pricing & reimbursement matters from the EU law and German law perspective. From 2008 to 2013, he was Head of the Brussels Office of Bundesverband der Pharmazeutischen Industrie e.V. (BPI). Before, he worked as a lawyer at Sträter Law Firm in Germany with a special focus on managed entry agreements and licensing of pharmaceuticals. Dr. Natz has also worked in the field of competition law with the European Commission and in the pharmaceutical industry. As a research assistant at Duke University (USA) he has dealt with international pharmaceutical law. His doctorate was supervised by the former judge at the European Court of Justice, Prof. Dr. Dr. Ulrich Everling
Email: natz@eucope.org
LinkedIn: https://www.linkedin.com/in/alexander-natz-63467433/
About EUCOPE:
For more than a decade, the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) has been the voice of small to mid-sized health technology companies in Europe. As a trade association, we advocate for sound public policy that supports innovation, while fostering a community built on a shared purpose: improving and saving the lives of European patients through innovative therapies and medical technology.
Website: https://www.eucope.org/
The Role of Patient Experience Data in Drug Development with Pina Haberl and Sam Morrison
World EPA Conference 2024 Special
Rare Disease Day Special 2024: The Role of Genetic Diagnosis in Rare Conditions with Nick Meade
Celebrating 5 Years of P4A: Reflections on Rare Diseases, Cell and Gene Therapies, and Legislation in Europe
Revolutionizing Patient Outcomes: The Power of Digital Health Solutions with RJ Kedziora
The Future of Patient Engagement and the Role of Technology in Healthcare with Iola Forster
Navigating the New EU HTA Regulation and Its Impact on ATMP Development
Alejandro Dorenbaum, CMO of Reneo Pharmaceuticals Discusses Clinical-Stage Therapies
Interview with Xortx Therapeutics CEO, Dr Allen Davidoff discussing their journey from early development to potential launch
World EPA Congress 2023 Special
Rare Disease Day Special 2023
Trends to look out for in 2023
World Orphan Drug Congress Europe 2022 Special
Winds of change for German Healthcare Market!
Part 2 -Patient Empowerment: Is it a no-brainer?
Part 1 Patient Empowerment; Why involving patients from early drug development through to launch is a no-brainer!
What makes P4A an award winning consultancy?
Special series with Eucope: Part 1 featuring Victor Maertens
China market access: obstacle or opportunity for orphan drug, cell and gene therapy manufacturers?
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Museum of the Missing
Strange by Nature Podcast
Sasquatch Chronicles
Hidden Brain